
NEW VISION LOSS WARNING: FDA Flags Rare Risk of Permanent Blindness Linked to Ozempic, Wegovy and Mounjaro
The U.S. Food and Drug Administration is requiring new safety warnings for widely prescribed diabetes and weight-loss medications, including Ozempic, Wegovy, Mounjaro and Zepbound, following findings suggesting a possible association between the drugs and a rare eye condition that can cause sudden, potentially permanent vision loss.
The warning concerns non-arteritic anterior ischemic optic neuropathy, known as NAION, a condition that develops when blood flow to the optic nerve is disrupted. Patients can experience an abrupt, painless loss of vision, usually affecting one eye, and the damage may be irreversible.
The medications belong to a group of treatments commonly referred to as GLP-1 drugs, which have become increasingly popular for controlling blood sugar and treating obesity. Ozempic and Wegovy contain semaglutide, while Mounjaro and Zepbound contain tirzepatide, a medication that acts on both GLP-1 and GIP receptors.
According to the findings described in Monday’s report, the FDA’s decision followed an analysis of 126 clinical trials involving 134,253 participants.
Researchers identified 15 possible cases of NAION across the studies, including 10 among patients receiving GLP-1 medications and five among participants receiving a placebo.
Although the number of reported cases was extremely small compared with the total study population, the findings raised concerns about a potential safety issue warranting additional warnings for patients and healthcare professionals.
The analysis does not establish that the medications directly cause the condition. Researchers have not determined precisely how the treatments might contribute to reduced blood flow to the optic nerve, and further investigation is needed to clarify the possible relationship.
According to the FDA’s analysis, the rate of NAION was approximately 6.4 cases per 100,000 patient-years among people receiving GLP-1 medications, compared with 3.8 cases per 100,000 patient-years among those receiving placebo or other blood-sugar-lowering treatments. The difference suggests a possible increase in risk, although the condition remains extremely rare.
The FDA also examined real-world medical records from patients with type 2 diabetes. That investigation found a higher risk among GLP-1 users compared with patients taking certain other diabetes medications, but no statistically significant increase when compared with another commonly prescribed class of treatments.
The agency’s investigation began after a 2024 study raised concerns about a possible connection between semaglutide and optic nerve damage. The FDA subsequently reviewed clinical trials, patient reports, observational studies and animal research before deciding that additional safety labeling was warranted.
Health officials are urging patients to recognize possible warning signs, including sudden vision loss, blurred vision, blind spots, missing sections of the visual field, changes in color perception or reduced sharpness of sight. Anyone experiencing these symptoms should seek immediate medical evaluation, even if there is no pain.
Doctors are being advised to arrange prompt ophthalmological examinations when NAION is suspected and to reassess whether affected patients should continue their GLP-1 medication.
The FDA also identified several factors that may independently increase the likelihood of NAION, including diabetes, high blood pressure, smoking, sleep apnea, anemia and kidney disease. Patients who have already experienced the condition in one eye face an increased risk of developing it in the other.
Novo Nordisk, the manufacturer of Ozempic and Wegovy, maintained that the available research does not establish a direct causal relationship between its medications and NAION. The company said it continues monitoring safety information and believes the treatments retain a favorable balance of benefits and risks.
Eli Lilly, which produces Mounjaro and Zepbound, said it is reviewing the FDA’s announcement.
Similar concerns have previously prompted regulatory action overseas. European authorities identified NAION as a very rare potential side effect of semaglutide, with an estimated frequency of up to one case per 10,000 patients treated for at least a year.
The FDA’s announcement does not constitute a recall or a recommendation that patients discontinue treatment. Patients currently taking the medications are advised not to stop them without consulting their prescribing physician, since doing so could disrupt diabetes management or other medically necessary treatment.